Zydus Lifesciences bags USFDA nod for Levothyroxine Sodium for Injection for myxedema coma treatment
The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India.
Advertisement
Ahmedabad: Pharma major, Zydus Lifesciences Limited, has received final approval for Levothyroxine Sodium for Injection, 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial from the United States Food and Drug Administration (USFDA).
Levothyroxine Sodium Injection is indicated for the treatment of myxedema coma. Myxedema coma is an extreme or decompensated form of hypothyroidism and while uncommon, is potentially lethal.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.